Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

The UK MHRA has approved AstraZeneca's Trixeo Aerosphere inhaler to treat adults with chronic obstructive pulmonary disease ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.

Abeona’s deal value is in line with recent voucher sale transactions amid uncertain times in rare disease drug development.

The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic ...

US President Donald Trump has signed an executive order telling drugmakers to cut prices to 'most favoured nation' pricing.